Today is just a short reflection on the efforts to vaccinate 330 M people. Thanks to discovery scientists exploring new means to initiate immune response to viruses, we saw a remarkably fast advanced development and manufacture of vaccines with > 90% efficacy in 9 months. The traditional vaccine platforms have historically required 5-7 years to…
As the SARS-CoV2 virus has surged across the US in the last month, EWP has seen increasing pressure on hospitals who are hard pressed to accommodate patients due to limitations in staff, space, and equipment. Although many facilities have invoked sophisticated resource sparing strategies, they are rapidly approaching the need to utilize crisis standards of…
We have seen this week a second vaccine developer approach the FDA for Emergency Use Authorization (EUA) of a new vaccine for SARS-CoV2. The race to the starting line has a couple winners, although we expect that more vaccine candidates will reach the stage of FDA review as we go through the winter and into…